Loading patent…
AssigneeJanssen Pharmaceutica NV
InventorsMarc Hubert Mercken, Marianne Borgers, Marc Maria Pierre Pelagie Vandermeeren, Bianca Julia J Van Broeck
Estimating the term…
The present invention provides monoclonal antibodies which specifically recognize the shorter Aβ peptides obtained after cleavage of the APP protein mediated by γ-secretase, i.e. the Aβ-peptide fragments Aβ1-37, Aβ3-37, Aβ3p-37, Aβ1-37 and Aβ11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the Aβx-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an Aβx-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of Aβx-37 peptides in a sample, such as a biological sample.
A monoclonal antibody which specifically recognizes Aβx-37 peptide and is produced by a hybridoma selected from the group consisting of JRD/Ab37/3 sc11 deposited at the Belgian Coordinated Collection of Microorganisms on Feb. 1, 2011 with accession number LMBP 8062CB, JRD/Ab37/4 sc11 deposited at the Belgian Coordinated Collection of Microorganisms on Feb. 1, 2011 with accession number LMBP 8063CB, and JRD/Ab37/10 sc11 deposited at the Belgian Coordinated Collections of Microorganisms on Mar. 30, 2011 with accession number LMBP 8064CB.
Dependencies are inferred from the claim text.